GI Dynamics’ EndoBarrier Gastrointestinal Liner has demonstrated blood sugar control and weight loss benefits beyond the implant period in the 12-Month Diabetes and Obesity trial.
EndoBarrier is a non-surgical device proven to lower blood glucose levels and promote weight loss in diabetic and obese patients during the implant period.
Go deeper with GlobalData
In the diabetes trial, type II diabetes patients treated with the EndoBarrier for 12 months achieved a mean 2.3% decrease in HbA1c levels, decreased glucose levels from an average of 175.6 at baseline to 137.8 mg/dL and 39% excess weight loss.
It is found that six months after removal of the EndoBarrier, patients experienced only a slight increase in HbA1c levels, from 6.5% to 6.6%.
In the obesity trial, patients reported an average of 46.4% excess weight loss, a mean reduction in HbA1c of 1.4% following 12 months of EndoBarrier treatment.
See Also:
Six months following the removal of the EndoBarrier, patients maintained as much as 75% of the weight they lost during the treatment period.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataThe EndoBarrier has received CE mark approval in Europe for implant periods of up to 12 months for treating type 2 diabetes and obesity, and recently received TGA approval in Australia.
